Skip to contentA
aTYR PHARMA INC
A
ATYRaTYR PHARMA INC Q1 2023 · 10-Q
Revenue$0.00$0.00no prior Q1 2022 on file Net Income-$11.95M-$11.95MN/M vs Q1 2022 EPS Diluted-$0.29-$0.29N/M vs Q1 2022 Operating Income-$12,787,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
aTYR PHARMA INC · CIK 1339970 · Engraved from SEC EDGAR
Free Cash Flowderived-$1,836,000N/M ended Mar 31, 2023 · filed May 9, 2023 · 39 d after period end